TMS-EEG Signatures of GABAergic Neurotransmission in the Human Cortex

• Published in: The Journal of neuroscience Vol. 34; no. 16; pp. 5603 - 5612
• Main Authors: Premoli, Isabella, Castellanos, Nazareth, Rivolta, Davide, Belardinelli, Paolo, Bajo, Ricardo, Zipser, Carl, Espenhahn, Svenja, Heidegger, Tonio, Müller-Dahlhaus, Florian, Ziemann, Ulf
• Format: Journal Article
• Language: English
• Published: United States Society for Neuroscience 16.04.2014
• Subjects: Adult; Brain Mapping; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalography; Electromyography; Evoked Potentials - drug effects; Evoked Potentials - physiology; GABA Agents - pharmacology; gamma-Aminobutyric Acid - metabolism; Humans; Male; Motor Cortex - drug effects; Motor Cortex - physiology; Synaptic Transmission - drug effects; Synaptic Transmission - physiology; Time Factors; Transcranial Magnetic Stimulation; Young Adult; GABA; electroencephalography; pharmaco-TMS-EEG; inhibition; human cortex; transcranial magnetic stimulation
• DOI: 10.1523/JNEUROSCI.5089-13.2014
• ISSN: 0270-6474; 1529-2401

Combining transcranial magnetic stimulation (TMS) and electroencephalography (EEG) constitutes a powerful tool to directly assess human cortical excitability and connectivity. TMS of the primary motor cortex elicits a sequence of TMS-evoked EEG potentials (TEPs). It is thought that inhibitory neurotransmission through GABA-A receptors (GABAAR) modulates early TEPs (<50 ms after TMS), whereas GABA-B receptors (GABABR) play a role for later TEPs (at ∼100 ms after TMS). However, the physiological underpinnings of TEPs have not been clearly elucidated yet. Here, we studied the role of GABAA/B-ergic neurotransmission for TEPs in healthy subjects using a pharmaco-TMS-EEG approach. In Experiment 1, we tested the effects of a single oral dose of alprazolam (a classical benzodiazepine acting as allosteric-positive modulator at α1, α2, α3, and α5 subunit-containing GABAARs) and zolpidem (a positive modulator mainly at the α1 GABAAR) in a double-blind, placebo-controlled, crossover study. In Experiment 2, we tested the influence of baclofen (a GABABR agonist) and diazepam (a classical benzodiazepine) versus placebo on TEPs. Alprazolam and diazepam increased the amplitude of the negative potential at 45 ms after stimulation (N45) and decreased the negative component at 100 ms (N100), whereas zolpidem increased the N45 only. In contrast, baclofen specifically increased the N100 amplitude. These results provide strong evidence that the N45 represents activity of α1-subunit-containing GABAARs, whereas the N100 represents activity of GABABRs. Findings open a novel window of opportunity to study alteration of GABAA-/GABAB-related inhibition in disorders, such as epilepsy or schizophrenia.